Figure 1 | Scientific Reports

Figure 1

From: Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer

Figure 1

Association between dNLR and grade ≥ 2 pneumonitis. (A) dNLR, and (B) dNLR28 in patients who did and did not experience grade ≥ 2 pneumonitis in the D group. (C) dNLR, and (D) dNLR28 in patients who experienced grade ≥ 2 pneumonitis in the non-D group. dNLR, derived neutrophil-to-lymphocyte ratio; D group, durvalumab group; non-D group, non-durvalumab group.

Back to article page